These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Feghali M; Venkataramanan R; Caritis S Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193 [TBL] [Abstract][Full Text] [Related]
23. Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Lim AC; Schuit E; Papatsonis D; van Eyck J; Porath MM; van Oirschot CM; Hummel P; Hasaart TH; Kleiverda G; de Graaf IM; van Ginkel AA; Mol BW; Bruinse HW Ultrasound Obstet Gynecol; 2012 Oct; 40(4):426-30. PubMed ID: 23008102 [TBL] [Abstract][Full Text] [Related]
24. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate. Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213 [TBL] [Abstract][Full Text] [Related]
25. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407 [TBL] [Abstract][Full Text] [Related]
26. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150 [TBL] [Abstract][Full Text] [Related]
27. Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth. Byrns MC J Steroid Biochem Mol Biol; 2014 Jan; 139():173-81. PubMed ID: 23410596 [TBL] [Abstract][Full Text] [Related]
29. Role of progestogens for the prevention of premature birth. Schindler AE J Steroid Biochem Mol Biol; 2005 Dec; 97(5):435-8. PubMed ID: 16198556 [TBL] [Abstract][Full Text] [Related]
30. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice. Romero R; Stanczyk FZ Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669 [No Abstract] [Full Text] [Related]
31. 17-α hydroxyprogesterone caproate for the prevention of preterm birth. Gupta S; Roman AS Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770 [TBL] [Abstract][Full Text] [Related]
32. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth. Hines M; Lyseng-Williamson KA; Deeks ED Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110 [TBL] [Abstract][Full Text] [Related]
34. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study. O'Brien JM; Ho SJ; Istwan NB; Stanziano GJ; Rhea DJ; Barton JR Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788 [TBL] [Abstract][Full Text] [Related]
35. 17-alpha-hydroprogesterone caproate and cervical changes. Facchinetti F Am J Obstet Gynecol; 2010 Sep; 203(3):e9; author reply e10. PubMed ID: 20537309 [No Abstract] [Full Text] [Related]
36. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. O'Brien JM Obstet Gynecol; 2012 Feb; 119(2 Pt 1):384-5; author reply 385-6. PubMed ID: 22270303 [No Abstract] [Full Text] [Related]
37. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. DeFranco EA; O'Brien JM; Adair CD; Lewis DF; Hall DR; Fusey S; Soma-Pillay P; Porter K; How H; Schakis R; Eller D; Trivedi Y; Vanburen G; Khandelwal M; Trofatter K; Vidyadhari D; Vijayaraghavan J; Weeks J; Dattel B; Newton E; Chazotte C; Valenzuela G; Calda P; Bsharat M; Creasy GW Ultrasound Obstet Gynecol; 2007 Oct; 30(5):697-705. PubMed ID: 17899571 [TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412 [TBL] [Abstract][Full Text] [Related]
39. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411 [TBL] [Abstract][Full Text] [Related]